Repositioning Candidate Details
| Candidate ID: | R1041 |
| Source ID: | DB06533 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Ragaglitazar |
| Synonyms: | Ragaglitazar |
| Molecular Formula: | C25H25NO5 |
| SMILES: | CCO[C@H](CC1=CC=C(OCCN2C3=CC=CC=C3OC3=C2C=CC=C3)C=C1)C(O)=O |
| Structure: |
|
| DrugBank Description: | -- |
| CAS Number: | 222834-30-2 |
| Molecular Weight: | 419.477 |
| DrugBank Indication: | Investigated for use/treatment in diabetes mellitus type 2. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | -- |
| Targets: | Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T03 | Peroxisome proliferator-activated receptor alpha | PPARA | agonist | Nuclear hormone receptor | Q07869 | PPARA_HUMAN | Details |
| T05 | Peroxisome proliferator-activated receptor gamma | PPARG | agonist | Nuclear hormone receptor | P37231 | PPARG_HUMAN | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |